These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25432408)

  • 1. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
    Lamont EB; Schilsky RL; He Y; Muss H; Cohen HJ; Hurria A; Meilleur A; Kindler HL; Venook A; Lilenbaum R; Niell H; Goldberg RM; Joffe S;
    J Natl Cancer Inst; 2015 Jan; 107(1):336. PubMed ID: 25432408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
    Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
    JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
    JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Generalizability of trial results to elderly medicare patients with advanced solid tumors.
    Mol L; Koopman M; Ottevanger PB; Punt CJ
    J Natl Cancer Inst; 2015 Jun; 107(6):djv104. PubMed ID: 25952033
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database.
    Caprario LC; Kent DM; Strauss GM
    J Thorac Oncol; 2013 Oct; 8(10):1272-81. PubMed ID: 24457238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
    Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
    JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
    Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
    Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
    Wang XQ; Liu J; Lin HS; Hou W
    Trials; 2016 Mar; 17(1):124. PubMed ID: 26956875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.
    Davidoff AJ; Tang M; Seal B; Edelman MJ
    J Clin Oncol; 2010 May; 28(13):2191-7. PubMed ID: 20351329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
    Hatfield LA; Huskamp HA; Lamont EB
    J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
    Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
    J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.
    Laccetti AL; Pruitt SL; Xuan L; Halm EA; Gerber DE
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25667420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study.
    Bearz A; Passalacqua R; Alabiso O; Cinieri S; Gridelli C; Cravesana C; Crinò L
    Clin Drug Investig; 2012 Nov; 32(11):755-60. PubMed ID: 23018280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
    Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
    Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
    Bridges BB; Thomas L; Hausner PF; Doyle LA; Bedor M; Smith R; Brahmer J; Edelman MJ
    Lung Cancer; 2008 Jul; 61(1):61-6. PubMed ID: 18201795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.